Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 18;31(1):175–185. doi: 10.1681/ASN.2019040416

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 by the American Society of Nephrology

PMC Copyright notice

Figure 3. — DGF-ESW interaction was generally homogeneous across subgroups and across KT outcomes. (A) Acute rejection, 1-year. (B) Death-censored graft failure. (C) Death. Estimates are aORs for acute rejection and aHRs for other outcomes, followed by 95% CIs. A low (<0.05) interaction P value indicates the association between ESW and the transplant outcome was significantly different between the IGF and DGF populations. Alem, alemtuzumab; ATG, anti-thymocyte globulin; IL2RA, IL-2 receptor antagonists.

Figure 3. — DGF-ESW interaction was generally homogeneous across subgroups and across KT outcomes. (A) Acute rejection, 1-year. (B) Death-censored graft failure. (C) Death. Estimates are aORs for acute rejection and aHRs for other outcomes, followed by 95% CIs. A low (<0.05) interaction P value indicates the association between ESW and the transplant outcome was significantly different between the IGF and DGF populations. Alem, alemtuzumab; ATG, anti-thymocyte globulin; IL2RA, IL-2 receptor antagonists.